What Resilience does

Resilience (National Resilience, Inc.) is a North American biopharmaceutical contract development and manufacturing organization (CDMO) founded in 2020 and headquartered in San Diego, California, with a planned relocation of corporate headquarters to Blue Ash, Ohio announced for June 2026. The company provides development, manufacturing, and fill/finish services across five therapeutic modalities — large molecule biologics, vaccines, nucleic acids (including mRNA), cell therapies, and gene therapies — operating from facilities in Blue Ash, Cincinnati, West Chester, Philadelphia, and Toronto, with international operations in Abu Dhabi, Saudi Arabia, and Taiwan through joint ventures.

The company's technology stack centers on a platform-plus-modules architecture: a core CDMO offering (Biologics, Cell Therapy, Aseptic Drug Product, and Device Assembly/Packaging) is layered with branded solutions including Auto-T (12-month T-cell clinical readiness), DAR-T (3-day autologous CAR-T), Idea to Clinic (~30% time savings for biologics), Build Your Resilience (secondary supplier readiness program), and Sprout Solutions (drug substance and fill/finish on-ramp). Specialized capabilities sit in three corporate vehicles: the wholly owned Ology Bioservices subsidiary (DoD-focused biologics including botulinum neurotoxin countermeasures), Resilience Government Services, Inc. (HHS/ASPR-aligned API and key starting materials production), and the CTMC joint venture with MD Anderson Cancer Center for cell therapy. Resilience also owns cell-free protein synthesis IP from the December 2021 SwiftScale Biologics acquisition and is a named customer of AWS's agentic AI life-sciences accelerators.

Resilience generates revenue through fee-for-service CDMO contracts across its four core service lines, supplemented by long-tail government contracts (U.S. Department of Defense, HHS/ASPR) and equity-backed international joint ventures. The company has raised more than $2 billion in equity since founding plus $1.235 billion in debt and government-backed financing ($410M DoD loan in 2023, $825M Oak Hill Advisors debt facility in 2025, $17.5M HHS grant in 2024), and operates with 501–1,000 employees. Customers include Moderna (COVID-19 mRNA), Parvus Therapeutics (autoimmune drug candidates), MD Anderson-related programs, and a long tail of small biotech and academic groups served through the CDMO network.

Name

Resilience

Legal name

National Resilience, Inc.

Website

https://resilience.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Resilience is a North American biopharmaceutical CDMO founded in 2020, providing development, manufacturing, and fill/finish services across biologics, vaccines, nucleic acids, cell therapy, and gene therapy from facilities in the US, Canada, UAE, Saudi Arabia, and Taiwan.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Testing Laboratories (8734)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Biopharmaceutical contract manufacturing
• Biologics CDMO services
• Cell therapy manufacturing
• Aseptic fill finish
• Drug product manufacturing

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Core offering

Resilience operates as a biopharmaceutical contract development and manufacturing organization (CDMO) providing end-to-end drug substance and drug product manufacturing across large molecule biologics, cell therapies, vaccines, and nucleic acids. The company runs a network of high-tech facilities in North America offering process development, GMP manufacturing, aseptic fill/finish for vials, cartridges and pre-filled syringes, and automated device assembly, packaging and logistics. Layered on top are named branded solutions — Sprout Solutions, Auto-T, DAR-T, Idea to Clinic, and Build Your Resilience — that package accelerated manufacturing workflows and secondary-supplier programs for customers.

Product overview

Resilience (National Resilience, Inc.) operates a platform-plus-modules CDMO architecture built around four core service lines: Large Molecule Biologics Development & Manufacturing, Cell Therapy Development & Manufacturing, Aseptic Drug Product Manufacturing, and Device Assembly, Packaging & Logistics. Layered on top of this core platform are five named branded solutions — Sprout Solutions™ (Drug Substance / Fill/Finish), Auto-T™ (12-month T-cell therapy manufacturing), DAR-T™ (3-day autologous CAR-T manufacturing), Idea to Clinic™ (~30% time savings for biologics path to clinic), and Build Your Resilience™ (secondary supplier readiness program). Specialized capabilities are delivered through the CTMC joint venture with MD Anderson (cell therapy), the Ology Bioservices subsidiary (biologics / DoD), and Resilience Government Services, Inc. (API / KSM manufacturing). The portfolio is supported across North American sites in Blue Ash (HQ), Cincinnati, Philadelphia, Toronto, and additional facilities, with regulatory expertise spanning the EU, Asia, the Middle East, and North America.

Differentiator

Problem solved

Functional benefit

Brands

• Sprout Solutions: Named solution for the next step in Drug Substance or Fill/Finish, with transparency, speed, and partnership from day one.
• Auto-T
• DAR-T
• Idea to Clinic
• Build Your Resilience

Products and services

• Sprout Solutions™ Branded solution for the next step in Drug Substance or Fill/Finish that nurtures customer molecules with transparency, speed, and partnership from day one.
• Auto-T™ Vetted manufacturing platform designed to help T cell-based therapies achieve clinical readiness in 12 months.
• DAR-T™ Autologous CAR-T manufacturing platform delivering doses in 3 days, accelerating access while ensuring precision and scalability.
• Idea to Clinic™ Biologics path-to-clinic program delivering approximately 30% time savings from start to finish using a proven stage-gate approach.
• Build Your Resilience™ Secondary supplier program offering three levels of readiness with full access to quality, supply chain, and commercial support on the customer's terms.
• Large Molecule Biologics Development & Manufacturing Platform-based development and manufacturing of large molecule biologics including monoclonal antibodies, recombinant proteins, and other complex molecules.
• Cell Therapy Development & Manufacturing Flexible, modular solutions for autologous and allogeneic cell therapies, including process and analytical development, GMP manufacturing, and release testing.
• Aseptic Drug Product Manufacturing End-to-end drug product development, scale-up, and tech transfer for vials, cartridges, and pre-filled syringes, built for speed, flexibility, and scale.
• Device Assembly, Packaging & Logistics Highly automated device assembly and packaging with cold and ambient storage capacity to support drug product supply and finished goods logistics.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability9 records

Recent moves16 records

Expansion highlights6 records

Direct peers

• Catalent: Catalent is one of the largest global CDMOs serving biologics, cell and gene therapy, and fill/finish across modalities that overlap directly with Resilience's core service lines. Both companies compete for biotech and pharma contract manufacturing business across similar therapeutic modalities.
• Lonza Group: Lonza is a leading global biologics and cell therapy CDMO offering mammalian and microbial biologics manufacturing, viral vectors, and cell therapy services that directly overlap with Resilience's biologics and cell therapy franchises. Both serve large biopharma and emerging biotech customers with end-to-end development and manufacturing services.
• Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth Biotechnologies is a major CDMO specializing in biologics, vaccines, and cell and gene therapy contract manufacturing, directly competing with Resilience across large molecule biologics and viral vector modalities. Both operate large-scale mammalian and microbial manufacturing capacity for biotech and pharma customers.
• Samsung Biologics: Samsung Biologics is a global CDMO providing mammalian cell culture biologics manufacturing at large scale, directly competing with Resilience's biologics CDMO offering. Both target innovator biopharma clients with end-to-end development, manufacturing, and aseptic fill/finish services.
• WuXi Biologics: WuXi Biologics is one of the largest biologics CDMOs globally, providing discovery, development, and manufacturing services for monoclonal antibodies and other biologics that overlap directly with Resilience's biologics franchise. Both compete for biotech and pharma outsourcing contracts across the full biologics lifecycle.
• AGC Biologics: AGC Biologics is a global CDMO offering microbial and mammalian biologics manufacturing, cell therapy, and gene therapy services. The company directly competes with Resilience across biologics and cell therapy modalities for biotech and pharma clients.
• OXB (Oxford BioMedica): OXB is a cell and gene therapy CDMO specializing in viral vector manufacturing and lentiviral-based therapies, and in October 2025 acquired Resilience's Durham facility. Both companies compete for cell therapy and gene therapy manufacturing contracts from biotech clients.
• KBI Biologics: KBI Biologics is a CDMO providing mammalian and microbial biologics process development and manufacturing services that overlap with Resilience's biologics franchise. Both serve small-to-mid-cap biotech customers with clinical and commercial biologics manufacturing needs.

Broad incumbents

• Thermo Fisher Scientific (Patheon CDMO): Thermo Fisher's Patheon CDMO business offers biologics, sterile fill/finish, and cell therapy services alongside its broader life sciences tools and diagnostics portfolio. While larger and more diversified than Resilience, its CDMO division competes directly for similar customers and contracts in biologics and drug product manufacturing.
• Charles River Laboratories: Charles River Laboratories operates a CDMO segment providing biologics, cell therapy, and vaccine manufacturing services that overlap with Resilience's offerings. While its core business is research models and preclinical services, its CDMO division competes for similar biotech manufacturing contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/IncResilience
• LinkedInlinkedin.com/company/weareresilience
• Facebookfacebook.com/NationalResilience

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries6 records

Funding overview

Funding rounds9 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resilience